Sanofi

#AI models #mRNA #Sanofi #ScionxBio #xRNA

ScionxBio collaborates to develop long-acting xRNA therapeutics 

ScionxBio, a preclinical-stage biotechnology company developing next-generation mRNA therapeutics, has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s platform.  The agreement brings together the global expertise of Sanofi’s mRNA… Read More

#News

#Acute inflammatory conditions #Autoimmune disease #Bispecific Antibodies #Collaboration #Earendil Labs #Sanofi

Sanofi and Earendil agree $2.56b bispecific antibodies deal

Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil’s discovery platform to multiple autoimmune and inflammatory disease programmes.  Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration.  According to the agreement Earendil Labs will receive up… Read More

#Business & Investment #News

Haematology
#ASH 2025 #Sanofi #Systemic mastocytosis

Ayvakit is safe long-term treatment for systemic mastocytosis 

New results show Ayvakit (avapritinib) is an effective and safe long-term treatment for systemic mastocytosis (SM).  The data, announced by Sanofi company Blueprint Medicines, showed Ayvakit led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in… Read More

#News

Osteoarthritis
#Arthritis #Investment #Sanofi

Sanofi backs Lifordi with investment for arthritis trial

Sanofi Ventures has invested in biotechnology company Lifordi Therapeutics, bringing Lifordi’s total financing round up to $112 million.  The funding is set to be used to support an ongoing Phase I study in Rheumatoid Arthritis (RA) by evaluating LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. It… Read More

#Business & Investment #News

Patient with type 1 diabetes
#FDA #Sanofi #Type 1 diabetes

FDA expedites review of Sanofi’s Type 1 diabetes drug

The US Food and Drug Administration (FDA) has accepted Sanofi’s Stage 3 Type 1 diabetes drug, Tzield, for expedited review.  Tzield delays the progression of Stage 3 Type 1 diabetes (T1D) in patients eight years or older who have recently been diagnosed. Sanofi’s drug received expedited review… Read More

#News #Regulatory

Dystrophin muscle protein
#FDA #Sanofi

FDA grants fast track designation to DM1 treatment SAR446268

The US Food and Drug Administration (FDA) has granted fast track designation to SAR446268 for the treatment of non-congenital DM1 myotonic dystrophy type 1 (DM1).  The announcement was made by pharmaceutical company Sanofi, who developed SAR446268 as a one-time gene therapy. Fast track designation will… Read More

#News

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Mergers and acquisitions #Respiratory #Sanofi #Vaccines #Vicebio

Harnessing molecular clamp technology for respiratory vaccines

Sanofi explores the acquisition of Vicebio and its Molecular Clamp technology, highlighting how it strengthens the company’s respiratory vaccine portfolio with next-generation combination candidates. Q: Sanofi has described the acquisition of Vicebio as a step toward next-generation combination vaccines. What gaps or opportunities does this address in your… Read More

#Exclusive Content

Eye
#Age-related diseases (ARDs) #AMD #Fast Track designation #FDA #Ophthalmology #Sanofi

FDA fast-tracks Sanofi’s AMD gene therapy

Sanofi’s investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD) has been granted fast track designation by the US Food and Drug Administration (FDA).   Sanofi’s SAR402663 is currently being evaluated in a Phase I/II clinical trial for patients with neovascular AMD. Read More

#News #Regulatory

Human brain
#Mergers and acquisitions #Neurodegenerative disorders #Neuroscience #Sanofi #Vigil Neuroscience

Sanofi completes acquisition of Vigil Neuroscience

Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline.  Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia.  Sanofi will also acquire Vigil’s preclinical pipeline… Read More

#Business & Investment #News

Heart
#Arrowhead Pharmaceuticals #Cardiometabolic diseases #China #RNA #Sanofi

Sanofi buys Chinese rights to cardiometabolic drug candidate

Sanofi has bought the rights to Arrowhead Pharmaceuticals first-in-class RNA interference (RNAi) therapeutic candidate for hypertriglyceridemia in Greater China.  Under the agreement, Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. … Read More

#Business & Investment #News

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple… Read More

#Cancer Research #News #Regulatory

Vaccine
#Immunology / Virology & Vaccines #Mergers and acquisitions #Sanofi #Vicebio

Sanofi acquires vaccine biotech Vicebio for $1.6 billion

Vicebio has agreed to be acquired by Sanofi for a total of $1.6 billion, including an upfront payment of $1.15 billion as well as development and regulatory milestones payments of $450 million.  Vicebio was created by Medicxi to develop vaccines for respiratory viruses utilising its proprietary Molecular… Read More

#Business & Investment #News

Sickle cells
#FDA #Orphan drugs #Rare disease #Sanofi #Sickle cell disorder (SCD)

Sanofi gets fourth orphan drug designation for rilzabrutinib

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib for sickle cell disease (SCD).  Rilzabrutinib is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur… Read More

#News #Regulatory